The platelet rich plasma market is estimated to witness a CAGR of 15.34% to grow to US$357.934 million in 2024 from US$152.020 million in 2018. Platelets or thrombocytes are the tiny blood cells that form clots or plug at the site of injury to stop bleeding. They are produced in the bone marrow along with the white and red blood cells. Blood plasma is the liquid portion of blood in which blood cells are suspended. It acts as a transport medium for delivering nutrients to the cells of the various organs of the body and for transporting waste products derived from cellular metabolism to the kidneys, liver, and lungs for excretion.
The blood platelet and plasma market is expected to show significant growth during the forecast period due to rising number of patients requiring plasma and platelet transfusion throughout the world, as platelets rich plasma blood is ensured to quick healing of injuries in bones and soft tissues, which are caused during sports, accidents, and others, as it uses the plasma concentrated out one’s own blood. The growing use of platelet-rich plasma in various therapeutic areas like during the facelift, hair growth, sports, and orthopedic surgeries will also augment the growth of the market. However, the high cost of plasma therapy and the threats or consequences associated with platelet-rich plasma might restrict the growth of the market during the given time frame.
The rise in the number of cosmetic surgeries.
Increased numbers of accidents in general.
This method is still underdeveloped and its effectiveness is still under observation.
The major players profiled in the platelets rich plasma market include DePuy Synthes, Regen Lab USA LLC, Harvest Technologies, Eclipse, Regenexx, Arthrex, Inc., Grifols International S.A., Bio Product Laboratory Ltd (BPL), Biolife Plasma Services, and Kedrion S.P.A.
The Platelet Rich Plasma market has been analyzed through the following segments:
Pure Platelet-Rich Plasma (P-PRP) or Leukocyte-Poor Platelet-Rich Plasma
Leukocyte-and Platelet-Rich Plasma (L-PRP)
Pure Platelet-Rich Fibrin (P-PRF)
Leukocyte- and Platelet-Rich Fibrin (L-PRF)
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Middle East and Africa